Adipose Tissue ReductionNCT04221646
Non-invasive Lipolysis on Human Thighs and Saddlebags
A study testing BTL-899 in people with Adipose Tissue Reduction, run by BTL Industries Ltd. at 1 site in Bulgaria.
Trial summary
The study is a prospective two-arm, open-label, interventional study with four treatment procedures and two follow-up visits. Read more about this study
- Who is it for?
- Ages 21 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Adipose Tissue Reduction
- What is being tested?
- BTL-899
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 47 participants
- Where
- 1 siteBulgaria
- Study dates
- 28 Jan 2020to 13 Nov 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Body Mass Index (BMI) of 20 to 35 kg/m2.
- Visible excess of adipose tissue at the treatment sites (ARM 1 - thigh area; ARM 2 - saddlebags area).
- Subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote body contouring and/or weight loss during study participation.
- No procedure for fat reduction (including cellulite treatment) in the last six months.
- Subjects willing and able to maintain his/her regular (pre-procedure) diet and exercise regimen without effecting a significant change of weight in either direction during study participation.
- Age between 21 and 70 years.
Who cannot join
- Electronic implants (such as intrauterine device, cardiac pacemakers, defibrillators, and neurostimulators)
- Cardiovascular diseases
- Vascular diseases (such as chronic venous insufficiency, deep venous thrombosis, varicose veins, etc.)
- Femoral or inguinal hernia
- Disturbance of temperature or pain perception
- Pulmonary insufficiency
Show all 24Show fewer
- Metal implants
- Drug pumps
- Malignant tumor
- Hemorrhagic conditions
- Septic conditions and empyema
- Acute inflammations
- Systemic or local infection such as osteomyelitis and tuberculosis
- Contagious skin disease
- Elevated body temperature
- Pregnancy
- Breastfeeding
- Injured or otherwise impaired muscles
- Scars, open lesions, and wounds at the treatment area
- Basedow's disease
- Previous liposuction in the treatment area in the last six months
- Unstable weight within the last 6 months (change in weight ± 3%)
- Previous body contouring or cellulite treatments in the thighs area in the last six months
- Any other disease or condition at the investigator's discretion
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect on BTL-899 Device for Non-invasive Lipolysis on Human Thighs and Saddlebags
The study is a prospective two-arm, open-label, interventional study with four treatment procedures and two follow-up visits.
Read the detailed description
This study aims to evaluate the clinical safety and efficacy of the BTL-899 device for non-invasive lipolysis and fat reduction in the thigh and saddlebag area. This is a prospective, open-label, two-arm study; therefore the participants will be assigned to two study groups. Each participant will complete 4 treatment visits and 2 follow-up visits.
- Conditions
- Adipose Tissue Reduction
- Being tested
- BTL-899
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BTL-899Device
Treatment with study device.
| Study group | Role | What they receive |
|---|---|---|
| Thighs circumference reduction | Experimental | The subjects will be enrolled and treated once per week. Both legs will be treated consecutively. The therapy will be applied simultaneously. Receives: Device: BTL-899 |
| Saddlebags fat thickness reduction | Experimental | The subjects will be enrolled and treated once per week. Both legs will be treated consecutively. The therapy will be applied consecutively too. Receives: Device: BTL-899 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in Fat Thickness Measured via Ultrasound
To gather clinical evidence that the BTL-899 device is able to induce non-invasive lipolysis when used on thighs and saddlebags. The fat thickness changes will be measured by means of ultrasound.
Measured: 6 months
Participants' Satisfaction Measured Via Questionnaires
Evaluation of the participants' satisfaction with the therapy via Therapy Satisfaction Questionnaires. Global Aesthetic Improvement Scale (Quality of Life questionnaire) will be used where score "3" means "very much improved" and "-3" is "very much worse".
Measured: 6 months
Evaluation of the Therapy's Safety Measured Via Therapy Comfort Questionnaire
The outcome will further be measured through the occurrence of adverse events or lack thereof. On Numerical Analog Scale (0-10), where 0 represents 'no pain' and 10 represents 'worst possible pain' select the level of pain experienced during the treatment.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jan 2020
- Study start28 Jan 2020
- Primary completion30 Oct 2020
- Study completion13 Nov 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adipose Tissue ReductionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 47 participants (actual)
Sponsor and investigators
- Lead sponsor
- BTL Industries Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04221646
- Sponsor's protocol ID
- BTL-899THI
- Status last verified
- Nov 2020
- First submitted
- 18 Dec 2019
- Last updated
- 25 Nov 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect on BTL-899 Device for Non-invasive Lipolysis on Human Thighs and Saddlebags
- ClinicalTrials.gov ID
- NCT04221646
- Acronym / sponsor ID
- BTL-899THI
- Conditions
- Adipose Tissue Reduction
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 47 participants (actual)
- Lead sponsor
- BTL Industries Ltd.Industry (pharma, biotech, devices)
- Study start
- 28 Jan 2020 (actual)
- Primary completion
- 30 Oct 2020 (actual)
- Study completion
- 13 Nov 2020 (actual)
- First posted
- 9 Jan 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study is a prospective two-arm, open-label, interventional study with four treatment procedures and two follow-up visits.
Detailed description
This study aims to evaluate the clinical safety and efficacy of the BTL-899 device for non-invasive lipolysis and fat reduction in the thigh and saddlebag area. This is a prospective, open-label, two-arm study; therefore the participants will be assigned to two study groups. Each participant will complete 4 treatment visits and 2 follow-up visits.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Thighs circumference reduction | Experimental | Device: BTL-899The subjects will be enrolled and treated once per week. Both legs will be treated consecutively. The therapy will be applied simultaneously. |
| Saddlebags fat thickness reduction | Experimental | Device: BTL-899The subjects will be enrolled and treated once per week. Both legs will be treated consecutively. The therapy will be applied consecutively too. |
Who may qualify
- Ages
- 21 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Body Mass Index (BMI) of 20 to 35 kg/m2.
- Visible excess of adipose tissue at the treatment sites (ARM 1 - thigh area; ARM 2 - saddlebags area).
- Subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote body contouring and/or weight loss during study participation.
- No procedure for fat reduction (including cellulite treatment) in the last six months.
- Subjects willing and able to maintain his/her regular (pre-procedure) diet and exercise regimen without effecting a significant change of weight in either direction during study participation.
Key exclusion criteria (24 listed)
- Electronic implants (such as intrauterine device, cardiac pacemakers, defibrillators, and neurostimulators)
- Cardiovascular diseases
- Vascular diseases (such as chronic venous insufficiency, deep venous thrombosis, varicose veins, etc.)
- Femoral or inguinal hernia
- Disturbance of temperature or pain perception
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BTL-899Treatment with study device. | Device | Saddlebags fat thickness reduction, Thighs circumference reduction |
Primary outcome
Changes in Fat Thickness Measured via Ultrasound
Time frame: 6 months
To gather clinical evidence that the BTL-899 device is able to induce non-invasive lipolysis when used on thighs and saddlebags. The fat thickness changes will be measured by means of ultrasound.
Participants' Satisfaction Measured Via Questionnaires
Time frame: 6 months
Evaluation of the participants' satisfaction with the therapy via Therapy Satisfaction Questionnaires. Global Aesthetic Improvement Scale (Quality of Life questionnaire) will be used where score "3" means "very much improved" and "-3" is "very much worse".
Evaluation of the Therapy's Safety Measured Via Therapy Comfort Questionnaire
Time frame: 6 months
The outcome will further be measured through the occurrence of adverse events or lack thereof. On Numerical Analog Scale (0-10), where 0 represents 'no pain' and 10 represents 'worst possible pain' select the level of pain experienced during the treatment.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Nov 2020.
- Individual participant dataSharing planned: No
Related trials for Adipose Tissue Reduction
Not yet recruiting
Impact of Significant Surgical Reduction of Adipose Tissue on Plasma Levels and Genetic Expression of Adipokines Associated With Ischemic Heart Disease in Type I Obesity.
Obesity & Overweight, Obesity Type I and II
RecruitingPhase 2
Finerenone After Catheter Ablation to Reduce Atrial Fibrillation Recurrence
Atrial Fibrillation (AF)
Not yet recruiting
Clinical Trial of the Cryosa System for the Treatment of Obstructive Sleep Apnea (OASIS)
Obstructive Sleep Apnea (OSA), Sleep Apnea - Obstructive
RecruitingPhase 1
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
End Stage Renal Disease
Recruiting
Targeting Sedentary Behavior Reduction and Physical Fitness Enhancement in Women Before and Beyond Bariatric Surgery- BARIMOV Study Protocol
Obesity (Disorder)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing BTL-899 in people with Adipose Tissue Reduction, run by BTL Industries Ltd. at 1 site in Bulgaria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Bulgaria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in Fat Thickness Measured via Ultrasound (time frame: 6 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Nov 2020.